Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics develops treatments for serious immunological diseases, with company updates centered on atacicept, a self-administered fusion protein designed to block BAFF and APRIL activity involved in autoantibody production. News commonly covers the atacicept program in IgA nephropathy, related autoimmune kidney disease research, clinical data from the ORIGIN and PIONEER programs, FDA regulatory communications, and preparations tied to potential commercialization.
Other recurring developments include quarterly financial results, balance sheet and financing commentary, participation in health care conferences, board and executive appointments, and equity-based inducement awards under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics (Nasdaq: VERA) appointed Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer effective March 25, 2026. Ms. Wright-Mitchell joins with over 25 years of life‑sciences legal and compliance experience and prior roles including general counsel and chief compliance officer.
She previously advised Vera as a strategic legal consultant and will lead legal efforts supporting regulatory approvals, commercialization, intellectual property management, and the potential launch of atacicept for IgA nephropathy.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards on March 3, 2026 under its 2024 Inducement Plan to six new employees. The grants include 46,000 non‑qualified stock options and 25,875 RSUs.
Options have an exercise price of $39.30 (closing price on March 3, 2026); options and RSUs vest over four years with 25% after one year and remaining vesting monthly or on annual anniversaries (Feb 20 or May 20, 2026) as applicable.
Vera Therapeutics (Nasdaq: VERA) appointed Christopher Hite to its Board of Directors effective March 5, 2026. Mr. Hite will serve as an independent director and brings over 25 years of strategic and financial leadership in biopharma, currently serving as Executive Vice President and Vice Chairman at Royalty Pharma.
The appointment coincides with Vera Therapeutics preparing for the potential launch of its dual BAFF/APRIL inhibitor atacicept for IgA nephropathy later in 2026, and management says Hite will support the company’s commercial and financial strategy.
Vera Therapeutics (NASDAQ: VERA) reported full-year 2025 results and a business update. Positive ORIGIN Phase 3 atacicept data were presented at ASN and published in NEJM, and the FDA granted priority review with a PDUFA date of July 7, 2026.
The company plans a potential mid-2026 U.S. commercial launch if approved. Vera completed equity and debt financings with combined potential gross proceeds of $800 million, and held $714.6 million in cash, equivalents and marketable securities at 12/31/2025. Net loss was $299.6 million for 2025.
Vera Therapeutics (Nasdaq: VERA) will present at multiple investor conferences in March 2026, including a TD Cowen fireside chat and one-on-one investor meetings at Barclays and Jefferies events.
The TD Cowen fireside chat is webcast on March 3, 2026 at 11:10am ET; a replay will be available for 90 days via the company’s Investor Calendar.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted on February 2, 2026 to two new employees under its 2024 Inducement Plan. The Compensation Committee granted non‑qualified stock options for 11,500 shares and RSUs for 5,750 shares.
Each option’s exercise price equals $45.28 (closing price on February 2, 2026). Options vest over four years with 25% after one year then monthly over 36 months; RSUs vest 25% on each anniversary of February 20, 2026, subject to continued service and plan terms.
Vera Therapeutics (Nasdaq: VERA) named Matt Skelton Chief Commercial Officer, effective January 28, 2026. Skelton, previously Executive Vice President, Commercial, joined Vera over a year ago and will lead launch readiness for atacicept targeting IgA nephropathy.
Skelton’s background includes scaling Seagen’s commercial organization to four approved products and senior commercial roles at Amgen and Eli Lilly.
Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards granted January 5, 2026 to 18 new employees under its 2024 Inducement Plan.
The Compensation Committee granted non-qualified stock options to purchase 228,750 shares and restricted stock units underlying 116,000 shares. Each option has an exercise price of $47.07, equal to the closing price on January 5, 2026.
Options vest over four years (25% at one year, then monthly over 36 months) subject to continued service; RSUs vest 25% on each anniversary of February 20, 2026 over four years. Awards are subject to the Inducement Plan and award agreements.
Vera Therapeutics (NASDAQ:VERA) announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 2:15 PM PST.
The team will participate in one-on-one investor meetings and provide a live webcast at the conference link. A replay will be available for 90 days via the company's Investor Calendar.
Vera Therapeutics (NASDAQ: VERA) announced the U.S. FDA accepted its BLA for atacicept in adults with immunoglobulin A nephropathy (IgAN) and granted Priority Review with a PDUFA target action date of July 7, 2026.
The submission used the Accelerated Approval Program and follows Breakthrough Therapy designation. A prespecified interim analysis from the ORIGIN 3 trial showed atacicept reduced proteinuria by 46% from baseline and by 42% versus placebo (p<0.0001) at week 36. Results were presented at ASn Kidney Week and published in the New England Journal of Medicine on November 6, 2025. If approved, atacicept could be offered as a once-weekly subcutaneous autoinjector for at-home use.